問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳宇欽
下載
2022-11-30 - 2027-10-31
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2022-03-01 - 2026-12-31
2020-07-01 - 2026-01-30
Participate Sites3Sites
Recruiting3Sites
2020-04-01 - 2026-09-01
Participate Sites4Sites
Recruiting4Sites
2023-06-01 - 2028-12-31
2023-12-01 - 2027-12-31
2020-07-24 - 2022-12-31
Participate Sites1Sites
Recruiting1Sites
2020-12-01 - 2021-12-31
2019-04-01 - 2022-12-31
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Participate Sites8Sites
Recruiting8Sites
Division of General Internal Medicine
2019-06-01 - 2023-02-09
Paroxysmal Nocturnal Hemoglobinuria
eculizumab (SB12 or EU sourced Soliris)
全部
